NCT01887288

Capecitabine With Digoxin for Metastatic Breast Cancer

Metronomic Capecitabine With Digoxin for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Western Regional Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the Growth Modulation Index (GMI) of the combination of metronomic capecitabine with oral digoxin in metastatic breast cancer

Detailed description

In this phase II study, the Investigators will combine metronomic capecitabine with digoxin to treat metastatic breast cancer patients who have progressed on both anthracyclines and taxanes. We hypothesize that the combination of digoxin with metronomic capecitabine may lead to increased efficacy and duration of treatment without progression with decreased side effects than standard regimen.

Conditions

• Metastatic Breast Cancer

Interventions

Type	Name	Description
DRUG	Capecitabine	650 mg/m\^2 PO b.i.d.
DRUG	Digoxin	0.25 mg once daily

Timeline

• Start date: 2013-04-01
• Primary completion: 2015-11-01
• Completion: 2015-11-01
• First posted: 2013-06-26
• Last updated: 2018-02-22
• Results posted: 2017-11-08

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study